HTAC PRELIMINARY RECOMMENDATION FOR GOVERNMENT FINANCING OF ZOLEDRONIC ACID for Individuals with Malignancy-Related Bone Disease
Revised HTAC preliminary recommendation on the inclusion of Insulin Detemir and the non-inclusion of Insulin glargine in the PNF
preliminary recommendation for the inclusion of insulin glargine and insulin detemir for type 1 and type 2 diabetes mellitus in the PNF
preliminary recommendation for the non-inclusion of eribulin in the treatment of soft tissue sarcoma in the PNF
preliminary recommendation for the inclusion of Potassium Citrate 1620 mg (15 mEq) tablet in the PNF.
